Cardiology

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.

Once a day readings over a year would detect 98.3% of the first Afib >24 hour episodes, while the probability of ≥1 false positive reading would be 98%.

Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

Lead SODIUM-HF investigator Justin Ezekowitz provides insight into the trial and why dietary interventions may still be important for heart failure care.

Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.

Larry Allen, MD, discusses some of ACC 2022's biggest contributions toward improving evidence-based care to patients with HF.

The majority of patients with HFrEF and RAASi-related hyperkalemia achieved optimal doses of RAASi when treated with patiromer.

No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.

In a new interview from ACC 2022, Florian Rader, MD discusses the potential of the new medication for HCM and the need to monitor safety signals over the long-term.

New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

A national survey assessment compared against the 6-item "ABCDs of ASCVD prevention" show the significant prevalence of obesity.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Results of the CHAP project demonstrate active treatment of chronic mild hypertension was associated with reductions in risk of adverse pregnancy outcomes and is unlikely to harm the developing child.

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.

Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.

Results of the VALOR-HCM trial indicate patients with hypertrophic cardiomyopathy could reduce their need for septal reduction therapy and improve quality of life with use of mavacamten, a selective cardiac myosin inhibitor from Bristol Myers Squibb.

New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.

A pilot study presented at ACC.22 demonstrates the impact of implementation of an RPM program to improve blood pressure control in patients with hypertension at primary care clinics.

New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.

An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.

Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients